Clinical Trial 18828

Cancer Type: Head & Neck
Interventions:

Study Type: Other
Phase of Study: NA
Investigators:

  • Heather Jim

Overview

Study Title

Smartphone-Based Assessment of Patient-Reported Outcomes Related to Receipt of Immunotherapy

Summary

The purpose of this study is to better understand the side effects that cancer patients experience while they are taking immunotherapy such as pembrolizumab, nivolumab, atezolizumab, or ipilimumab. Investigators hope to use this information to help better educate future patients who are taking immunotherapy, on what to expect and how to feel their best.

Objective

To understand patients, caregivers, and oncologists perspectives about irAEs through qualitative data collection. To quantitatively characterize the frequency, severity, and longitudinal course of patient-reported irAEs and changes in quality of life secondary to receipt of an immune checkpoint inhibitor.

Inclusion Criteria

ELIGIBLE PATIENTS:

  • Age 18 years or older
  • Diagnosed with cancer
  • Currently receiving treatment with pembrolizumab, nivolumab, atezolizumab, or ipilimumab at Moffitt Cancer Center or Thomas Jefferson University or related affiliates
  • Able to speak and read English or Spanish
  • Able to provide informed consent
  • Potential participants will be identified in a HIPAA-compliant manner by a trained research associate through review of scheduled outpatient appointments with medical oncologists. A bilingual research associate will approach Spanish-speaking patients. Eligibility will be determined by the research associate through chart review, discussion with the treatment team, and confirmation with the patient. Eligible patients and their informal caregiver will be invited to participate in separate, simultaneous focus groups. ELIGIBLE CAREGIVERS:
  • Age 18 years or older
  • Able to speak and read English or Spanish
  • Note: Patients without an informal caregiver are still eligible to participate. Spanish-language focus groups will be conducted for Spanish speaking participants.